SE9703205D0 - Ny kristallform av 2-metyl-4-(4-metyl-1-piperazinyl)-10H-tieno (2,3-b) (1,5)bensodiazepin och framställning därav - Google Patents
Ny kristallform av 2-metyl-4-(4-metyl-1-piperazinyl)-10H-tieno (2,3-b) (1,5)bensodiazepin och framställning däravInfo
- Publication number
- SE9703205D0 SE9703205D0 SE9703205A SE9703205A SE9703205D0 SE 9703205 D0 SE9703205 D0 SE 9703205D0 SE 9703205 A SE9703205 A SE 9703205A SE 9703205 A SE9703205 A SE 9703205A SE 9703205 D0 SE9703205 D0 SE 9703205D0
- Authority
- SE
- Sweden
- Prior art keywords
- methyl
- benzodiazepine
- thieno
- piperazinyl
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40956695A | 1995-03-24 | 1995-03-24 | |
PCT/US1996/003917 WO1996030375A1 (en) | 1995-03-24 | 1996-03-22 | Process and crystal forms of 2-methyl-thieno-benzodiazepine |
Publications (2)
Publication Number | Publication Date |
---|---|
SE9703205D0 true SE9703205D0 (sv) | 1997-09-05 |
SE9703205L SE9703205L (sv) | 1997-09-05 |
Family
ID=23621056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE9703205A SE9703205L (sv) | 1995-03-24 | 1997-09-05 | Ny kristallform av 2-metyl-4-(4-metyl-1-piperazinyl)-10H-tieno (2,3-b) (1,5)bensodiazepin och framställning därav |
Country Status (49)
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EG23659A (en) * | 1995-03-24 | 2007-03-26 | Lilly Co Eli | Process and crystal forms of methyl-thieno-benzodiazepine |
US6274636B1 (en) * | 1995-09-29 | 2001-08-14 | Eli Lilly And Company | Method for treating a tic disorder |
UA57727C2 (ru) * | 1996-03-11 | 2003-07-15 | Елі Ліллі Енд Компані | Способ лечения чрезмерной агрессивности |
EP0904083A4 (en) * | 1996-03-25 | 2002-05-22 | Lilly Co Eli | METHOD FOR ANESTHESIA |
IL126064A0 (en) * | 1996-03-25 | 1999-05-09 | Lilly Co Eli | Method for treating pain |
EA000769B1 (ru) * | 1996-03-25 | 2000-04-24 | Эли Лилли Энд Компани | Способ лечения при боли, вызванной мигренью |
IL126203A (en) * | 1996-03-25 | 2002-12-01 | Lilly Co Eli | A synergistic painkiller that contains olenzapine and another painkiller |
TR199900639T2 (xx) * | 1996-09-23 | 1999-06-21 | Eli Lilly And Company | Olanzapin dihidrat D. |
ZA978515B (en) * | 1996-09-23 | 1999-03-23 | Lilly Co Eli | Intermediates and process for preparing olanzapine |
US20030022889A1 (en) * | 1997-04-15 | 2003-01-30 | Bymaster Franklin P. | Method for providing neuro-protective effects |
ZA982917B (en) * | 1997-04-15 | 1999-10-06 | Lilly Co Eli | Method for treating cerebral focal stroke. |
AU6955998A (en) * | 1997-04-15 | 1998-11-11 | Eli Lilly And Company | Method for providing neuro-protective effects |
EP1155696B1 (en) * | 1997-04-15 | 2004-03-03 | Eli Lilly And Company | Use of olanzapine for the manufacture of a medicament for neuroprotection |
USRE43932E1 (en) | 1997-07-18 | 2013-01-15 | Novartis Ag | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
US6617321B2 (en) | 1997-09-30 | 2003-09-09 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine formulation |
NZ510208A (en) * | 1998-09-30 | 2003-04-29 | Lilly Co Eli | Olanzapine (2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine) pamoate salt |
FR2802101B1 (fr) | 1999-12-10 | 2003-02-28 | Aventis Pharma Sa | Association de cymemazine et d'un neuroleptique atypique |
US6348458B1 (en) | 1999-12-28 | 2002-02-19 | U & I Pharmaceuticals Ltd. | Polymorphic forms of olanzapine |
US7022698B2 (en) | 1999-12-28 | 2006-04-04 | U & I Pharmaceuticals, Ltd. | Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof |
ATE293113T1 (de) * | 1999-12-28 | 2005-04-15 | Cipla Ltd | Neue polymorphe formen von olanzapin |
WO2002018390A1 (en) * | 2000-08-31 | 2002-03-07 | Dr. Reddy's Laboratories Ltd. | Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine |
AU2001282913A1 (en) * | 2000-09-08 | 2002-03-22 | Eli Lilly And Company | A method of treating weight gain associated with atypical antipsychotic use |
US6740753B2 (en) * | 2001-01-04 | 2004-05-25 | Geneva Pharmaceuticals, Inc. | Olanzapine crystal modification |
EP1440074A1 (en) * | 2001-10-29 | 2004-07-28 | Dr. Reddy's Laboratories Ltd. | Olanzapine dihydrate-ii a process for its preparation and use thereof |
US6906062B2 (en) | 2001-12-24 | 2005-06-14 | Sun Pharmaceutical Industries Limited | Crystalline form I of 2-methyl-4-(4-menthyl-1-piperazinyl) 10H thieno [2,3-b][1,5]benzodiazepine |
WO2004089313A2 (en) * | 2003-04-01 | 2004-10-21 | Transform Pharmaceuticals, Inc. | Novel olanzapine forms and related methods of treatment |
US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
US7790905B2 (en) * | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
US20100311701A1 (en) * | 2002-02-15 | 2010-12-09 | Transform Pharmaceuticals, Inc | Pharmaceutical Co-Crystal Compositions |
AU2003217676B2 (en) | 2002-02-22 | 2009-06-11 | Takeda Pharmaceutical Company Limited | Active agent delivery systems and methods for protecting and administering active agents |
EP1494998A2 (en) * | 2002-03-01 | 2005-01-12 | University Of South Florida | Multiple-component solid phases containing at least one active pharmaceutical ingredient |
PL196814B1 (pl) * | 2002-05-17 | 2008-02-29 | Inst Farmaceutyczny | Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty |
ATE500258T1 (de) | 2002-05-31 | 2011-03-15 | Sandoz Ag | Verfahren zur herstellung von olanzapin form i |
CA2489984A1 (en) * | 2002-06-21 | 2003-12-31 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions with improved dissolution |
SI21270A (sl) * | 2002-07-15 | 2004-02-29 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Kristalne oblike olanzapina in postopki za njihovo pripravo |
PL202856B1 (pl) * | 2002-12-20 | 2009-07-31 | Adamed Spo & Lstrok Ka Z Ogran | Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny |
EP1575962A1 (en) | 2002-12-24 | 2005-09-21 | Teva Pharmaceutical Industries Limited | Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms |
US8183290B2 (en) | 2002-12-30 | 2012-05-22 | Mcneil-Ppc, Inc. | Pharmaceutically acceptable propylene glycol solvate of naproxen |
US20060135547A1 (en) * | 2003-03-12 | 2006-06-22 | Toth Zoltan G | Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine |
PL1507531T3 (pl) * | 2003-03-12 | 2007-06-29 | Teva Pharma | Trwałe kompozycje farmaceutyczne desloratadyny |
GB0314149D0 (en) * | 2003-06-18 | 2003-07-23 | Generics Uk Ltd | Novel amorphous forms |
GB0326148D0 (en) | 2003-11-10 | 2003-12-17 | Lilly Co Eli | Morpholine derivatives |
CA2546200A1 (en) * | 2003-11-18 | 2005-06-02 | 3M Innovative Properties Company | Olanzapine containing transdermal drug delivery compositions |
WO2005063771A1 (en) * | 2003-12-22 | 2005-07-14 | Teva Pharmaceutical Industries Ltd | Methods of preparing olanzapine |
US20050272720A1 (en) * | 2004-01-27 | 2005-12-08 | Rolf Keltjens | Process for making olanzapine Form I |
WO2005070938A1 (en) | 2004-01-27 | 2005-08-04 | Synthon B.V. | Stable salts of olanzapine |
ES2253091B1 (es) * | 2004-07-27 | 2007-02-01 | Inke, S.A. | Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo. |
WO2006027800A1 (en) * | 2004-09-06 | 2006-03-16 | Shasun Chemicals And Drugs Limited | A novel process for preparation of a pharmaceutically pure polymorphic form 1 of olanzapine |
CA2587710C (en) * | 2004-11-16 | 2014-10-21 | Elan Pharma International Ltd. | Injectable nanoparticulate olanzapine formulations |
DK1838716T3 (da) | 2005-01-05 | 2011-07-25 | Lilly Co Eli | Olanzapinpamota-dihydrat |
CZ200563A3 (cs) * | 2005-02-02 | 2006-10-11 | Zentiva, A. S. | Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby |
BRPI0608484E2 (pt) * | 2005-03-21 | 2014-10-29 | Reddys Lab Ltd Dr | Processo de preparação da forma i cristalina de olanzapina |
US20070021605A1 (en) * | 2005-07-20 | 2007-01-25 | Rolf Keltjens | Process and composition for making olanzapine form i |
EP1919923A1 (en) * | 2005-08-17 | 2008-05-14 | Synthon B.V. | A process for making olanzapine form i |
GB0522474D0 (en) | 2005-11-03 | 2005-12-14 | Actavis Group | A pharmaceutical formulation |
HUP0501046A2 (en) * | 2005-11-11 | 2007-08-28 | Egis Gyogyszergyar Nyilvanosan | Process for the preparation of olanzapine |
US8222184B2 (en) | 2006-03-07 | 2012-07-17 | Ncr Corporation | UV and thermal guard |
US8721202B2 (en) | 2005-12-08 | 2014-05-13 | Ncr Corporation | Two-sided thermal print switch |
US8367580B2 (en) | 2006-03-07 | 2013-02-05 | Ncr Corporation | Dual-sided thermal security features |
ES2279715B1 (es) | 2005-12-26 | 2008-06-01 | Laboratorios Lesvi, S.L. | Formulacion oral de olanzapina. |
US7834176B2 (en) | 2006-01-26 | 2010-11-16 | Sandoz Ag | Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E |
WO2007134845A2 (en) * | 2006-05-18 | 2007-11-29 | Synthon B.V. | Olanzapine pharmaceutical composition |
US20080138409A1 (en) * | 2006-09-29 | 2008-06-12 | Osinga Niels J | Olanzapine pharmaceutical composition |
US7718649B1 (en) | 2006-11-10 | 2010-05-18 | Pisgah Labs, Inc. | Physical states of a pharmaceutical drug substance |
US8039461B1 (en) | 2006-11-10 | 2011-10-18 | Pisgah Laboratories, Inc. | Physical states of a pharmaceutical drug substance |
PL381564A1 (pl) | 2007-01-22 | 2008-08-04 | Koźluk Tomasz Nobilus Ent | Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny |
CA2591644A1 (en) * | 2007-06-14 | 2008-12-14 | Apotex Pharmachem Inc. | Novel processes to form-i of olanzapine |
US9056488B2 (en) | 2007-07-12 | 2015-06-16 | Ncr Corporation | Two-side thermal printer |
US8883863B1 (en) | 2008-04-03 | 2014-11-11 | Pisgah Laboratories, Inc. | Safety of psuedoephedrine drug products |
CN101735239B (zh) * | 2008-11-06 | 2011-08-31 | 齐鲁制药有限公司 | 一种无水奥氮平晶型ii的制备方法 |
EP2292624A1 (en) | 2009-07-20 | 2011-03-09 | LEK Pharmaceuticals d.d. | Process for the purification of olanzapine |
HRP20240109T1 (hr) | 2010-08-23 | 2024-03-29 | Alkermes Pharma Ireland Limited | Postupci za liječenje povećanja tjelesne težine induciranog antipsihoticima |
CN102093386B (zh) * | 2011-01-05 | 2016-06-01 | 浙江华海药业股份有限公司 | 一种制备奥兰扎平晶型ⅱ的方法 |
WO2012153347A2 (en) | 2011-05-04 | 2012-11-15 | Zentiva K.S. | Oral pharmaceutical composition of olanzapine form 1 |
ES2926662T3 (es) | 2012-08-21 | 2022-10-27 | Janssen Pharmaceutica Nv | Anticuerpos contra haptenos de risperidona y uso de los mismos |
CN104755093B (zh) * | 2012-08-21 | 2018-11-16 | 詹森药业有限公司 | 奥氮平半抗原的抗体及其用途 |
US9494608B2 (en) | 2012-08-21 | 2016-11-15 | Janssen Pharmaceutica Nv | Antibodies to olanzapine and use thereof |
CA2891122C (en) | 2012-11-14 | 2021-07-20 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
CN103848847B (zh) * | 2012-12-04 | 2018-02-06 | 广东东阳光药业有限公司 | 一种改进制备奥氮平及其晶型ii的方法 |
JP6008734B2 (ja) * | 2012-12-20 | 2016-10-19 | 株式会社トクヤマ | オランザピンii型結晶の製造方法 |
CN103145731B (zh) * | 2013-02-26 | 2014-02-19 | 江苏豪森药业股份有限公司 | 奥氮平晶型及其制备方法和用途 |
WO2023139531A1 (en) | 2022-01-20 | 2023-07-27 | Teva Pharmaceuticals International Gmbh | Olanzapine, compositions thereof and methods of use thereof |
US20240238308A1 (en) | 2023-01-10 | 2024-07-18 | Medincell Sa | Olanzapine compositions and methods of use |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4115568A (en) * | 1974-11-26 | 1978-09-19 | Lilly Industries Limited | Thieno[3,2-b]-[1,5]benzodiazepines |
GB1548022A (en) | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
CA1097233A (en) | 1977-07-20 | 1981-03-10 | George K. E. Gregory | Packages |
US4237279A (en) * | 1979-07-27 | 1980-12-02 | Eli Lilly And Company | Crystalline 3-hydroxycephalosporin solvates |
IE53696B1 (en) | 1981-12-02 | 1989-01-18 | Wyeth John & Brother Ltd | Solid shaped articles |
US5079018A (en) | 1989-08-14 | 1992-01-07 | Neophore Technologies, Inc. | Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs |
US5039540A (en) | 1989-08-14 | 1991-08-13 | Neophore Technologies, Inc. | Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs |
GB9009229D0 (en) * | 1990-04-25 | 1990-06-20 | Lilly Industries Ltd | Pharmaceutical compounds |
US5229382A (en) * | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
ES2153373T3 (es) * | 1992-05-29 | 2001-03-01 | Lilly Co Eli | Derivados de tienobenzodiazepina para el tratamiento de trastornos del sistema nervioso central. |
US5439888A (en) * | 1994-03-04 | 1995-08-08 | Eli Lilly And Company | Antithrombotic agents |
US5457101A (en) * | 1994-06-03 | 1995-10-10 | Eli Lilly And Company | Thieno[1,5]benzoidiazepine use |
EG23659A (en) * | 1995-03-24 | 2007-03-26 | Lilly Co Eli | Process and crystal forms of methyl-thieno-benzodiazepine |
-
1996
- 1996-03-21 EG EG19960250A patent/EG23659A/xx active
- 1996-03-22 CO CO96014567A patent/CO4650278A1/es unknown
- 1996-03-22 EE EE9700232A patent/EE03489B1/xx not_active IP Right Cessation
- 1996-03-22 PT PT03077455T patent/PT1445259E/pt unknown
- 1996-03-22 CN CN96192775A patent/CN1065536C/zh not_active Expired - Lifetime
- 1996-03-22 YU YU17796A patent/YU49478B/sh unknown
- 1996-03-22 NZ NZ306110A patent/NZ306110A/en not_active IP Right Cessation
- 1996-03-22 ZA ZA9602342A patent/ZA962342B/xx unknown
- 1996-03-22 CA CA002214005A patent/CA2214005C/en not_active Expired - Fee Related
- 1996-03-22 EP EP03077455A patent/EP1445259B1/en not_active Expired - Lifetime
- 1996-03-22 AT AT03077455T patent/ATE331719T1/de active
- 1996-03-22 PE PE1996000203A patent/PE44897A1/es not_active IP Right Cessation
- 1996-03-22 SI SI9630636T patent/SI1095941T1/xx unknown
- 1996-03-22 IL IL11761096A patent/IL117610A/xx not_active IP Right Cessation
- 1996-03-22 EA EA199700262A patent/EA000149B1/ru not_active IP Right Cessation
- 1996-03-22 HU HU9802824A patent/HU224989B1/hu not_active IP Right Cessation
- 1996-03-22 DK DK96302000T patent/DK0733635T3/da active
- 1996-03-22 TW TW085103499A patent/TW513432B/zh not_active IP Right Cessation
- 1996-03-22 AT AT00203573T patent/ATE251627T1/de active
- 1996-03-22 CH CH02245/97A patent/CH690579A5/de not_active IP Right Cessation
- 1996-03-22 DK DK00203573T patent/DK1095941T3/da active
- 1996-03-22 MY MYPI96001085A patent/MY114701A/en unknown
- 1996-03-22 SI SI9630743T patent/SI1445259T1/sl unknown
- 1996-03-22 SI SI9620040A patent/SI9620040B/sl not_active IP Right Cessation
- 1996-03-22 AU AU54279/96A patent/AU706471B2/en not_active Ceased
- 1996-03-22 AT AT0902196A patent/AT406771B/de not_active IP Right Cessation
- 1996-03-22 GB GB9719819A patent/GB2313835B/en not_active Expired - Fee Related
- 1996-03-22 DE DE69614426T patent/DE69614426T2/de not_active Expired - Lifetime
- 1996-03-22 LU LU90096A patent/LU90096B1/fr active
- 1996-03-22 DK DK03077455T patent/DK1445259T3/da active
- 1996-03-22 ES ES00203573T patent/ES2208220T3/es not_active Expired - Lifetime
- 1996-03-22 DE DE69636313T patent/DE69636313T2/de not_active Expired - Lifetime
- 1996-03-22 ES ES03077455T patent/ES2266719T3/es not_active Expired - Lifetime
- 1996-03-22 PL PL96322501A patent/PL183723B1/pl not_active IP Right Cessation
- 1996-03-22 KR KR1019970706591A patent/KR100399688B1/ko not_active IP Right Cessation
- 1996-03-22 AT AT96302000T patent/ATE204280T1/de active
- 1996-03-22 TR TR97/01017T patent/TR199701017T1/xx unknown
- 1996-03-22 ZA ZA9602344A patent/ZA962344B/xx unknown
- 1996-03-22 AR ARP960101876A patent/AR002719A1/es unknown
- 1996-03-22 UA UA97094737A patent/UA44765C2/uk unknown
- 1996-03-22 SK SK1218-97A patent/SK284143B6/sk not_active IP Right Cessation
- 1996-03-22 PT PT00203573T patent/PT1095941E/pt unknown
- 1996-03-22 JP JP8529532A patent/JPH11502535A/ja not_active Ceased
- 1996-03-22 EP EP00203573A patent/EP1095941B1/en not_active Expired - Lifetime
- 1996-03-22 PT PT96302000T patent/PT733635E/pt unknown
- 1996-03-22 ES ES96302000T patent/ES2159346T3/es not_active Expired - Lifetime
- 1996-03-22 DE DE69630324T patent/DE69630324T2/de not_active Expired - Lifetime
- 1996-03-22 WO PCT/US1996/003917 patent/WO1996030375A1/en active IP Right Grant
- 1996-03-22 CZ CZ19973000A patent/CZ292688B6/cs not_active IP Right Cessation
- 1996-03-22 SI SI9630345T patent/SI0733635T1/xx unknown
- 1996-03-22 EP EP96302000A patent/EP0733635B1/en not_active Expired - Lifetime
- 1996-03-22 AR ARP960101875A patent/AR010448A1/es unknown
- 1996-03-22 TW TW085103500A patent/TW442488B/zh not_active IP Right Cessation
- 1996-03-22 AP APAP/P/1997/001065A patent/AP828A/en active
- 1996-03-22 DE DE19681286T patent/DE19681286T1/de not_active Withdrawn
- 1996-03-22 RO RO97-01761A patent/RO118872B1/ro unknown
- 1996-03-22 BR BR9607790A patent/BR9607790A/pt not_active IP Right Cessation
- 1996-05-09 SV SV1996000031A patent/SV1996000031A/es not_active Application Discontinuation
- 1996-07-25 US US08/686,989 patent/US5736541A/en not_active Expired - Lifetime
- 1996-10-18 PA PA19968353701A patent/PA8353701A1/es unknown
-
1997
- 1997-09-05 SE SE9703205A patent/SE9703205L/xx not_active Application Discontinuation
- 1997-09-08 LV LVP-97-163A patent/LV12018B/en unknown
- 1997-09-16 LT LT97-148A patent/LT4349B/lt not_active IP Right Cessation
- 1997-09-22 FI FI973750A patent/FI973750A0/fi unknown
- 1997-09-22 BG BG101900A patent/BG62619B1/bg unknown
- 1997-09-22 IS IS4564A patent/IS1896B/is unknown
- 1997-09-22 NO NO19974365A patent/NO314663B1/no not_active IP Right Cessation
- 1997-09-23 DK DK108997A patent/DK108997A/da not_active Application Discontinuation
- 1997-09-24 OA OA70082A patent/OA10510A/en unknown
-
1998
- 1998-12-23 HK HK98115175A patent/HK1013988A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE9703205D0 (sv) | Ny kristallform av 2-metyl-4-(4-metyl-1-piperazinyl)-10H-tieno (2,3-b) (1,5)bensodiazepin och framställning därav | |
FI101538B (fi) | Menetelmä uusien, terapeuttisesti käyttökelpoisten 2-metyyli-4-(4-mety yli-1-piperatsinyyli)-10H-tieno£2,3-b|£1,5|bentsodiatsepiinijohdannais ten valmistamiseksi | |
HUP9800410A2 (hu) | Szájon át adható 2-metil-tieno-benzodiazepin-készítmény | |
AU2003237305A1 (en) | Process of preparation of olanzapine form i | |
HUP0000065A2 (hu) | Olanzapin-dihidrát D és az azt tartalmazó gyógyszerkészítmények | |
NZ510208A (en) | Olanzapine (2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine) pamoate salt | |
IL117971A (en) | Pharmaceutical compositions containing olanzapine for treating dyskinesias | |
DK0733634T3 (da) | Fremgangsmåde til fremstilling af et thieno(2,3-b) (1,5)benzodiazepinderivat | |
NO20040658L (no) | Fremgansmate for fremstillingen av olanzapin og et intermediat derfor. | |
HUP0401157A2 (hu) | Liofilizált metil-tieno-benzodiazepin készítmény, előállítása és alkalmazása | |
NZ332037A (en) | Olanzapine for treating migraine pain | |
PT828494E (pt) | Compostos farmaceuticos | |
WO2003037903A8 (en) | Olanzapine dihydrate-ii a process for its preparation and use thereof | |
DK0831835T3 (da) | Behandling af anorexia | |
DE59608617D1 (de) | 4a,5a,8a,8b-TETRAHYDRO-6H-PYRROLO 3',4':4,5]FURO 3,2-b]PYRIDIN-6,8(7H)-DION DERIVATE ZUR BEKÄMPFUNG VON ENDOPARASITEN UND VERFAHREN ZU IHRER HERSTELLUNG | |
ECSP961694A (es) | Procedimeinto para preparar olanzapina (caso x - 9992m) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NAV | Patent application has lapsed |